Public Health Surveillance 2030: Report on Regional Consultations

Surveillance is one of the six core functions of public health in Canada1. Public health surveillance has been defined as, “the continuous and systematic collection, orderly consolidation and evaluation of pertinent data with prompt dissemination of results to those who need to know, particularly those who are in a position to take action”2. Surveillance is…

Understanding and Assessing Quantitative Modelling Research

This document provides an overview of how to critically assess a research article which uses quantitative, data-driven mathematical modelling to examine infectious disease transmission. Included is a Quick Reference Guide which aligns with the process of quantitative model development and the format of research articles and is meant to assist in a critical review of the research.

Multi-Drug Resistant Tuberculosis: Proceedings from a Virtual Discussion with Public Health Decision- makers and Practitioners in Canada

This report summarizes the proceedings of a dialogue on MDR-TB care in Canada which was held online April 25 and 26, 2023. The event brought together 31 participants, some with lived experience of MDR-TB and some who were policy makers, researchers, and public health personnel from different regions in Canada. The intent of the dialogue was to provide an opportunity for stakeholders to discuss current challenges to the provision of effective, equitable MDR-TB care in Canada and possible solutions.

Out of the ashes: Ashcroft Indian Band and the Elephant Hill wildfire – Insights for public health responses to long-term evacuation

This case study by the National Collaborating Centres for Public Health (NCCPH) explores the evacuation of Ashcroft Indian Band following the Elephant Hill wildfire in 2017. It includes insight into the health and social impacts of the evacuation, as well as the role of public health to support long-term emergency planning and recovery.

Therapeutics for mpox

There are two anti-viral treatments used for smallpox that have been repurposed for mpox, tecovirimat and brincidofovir, of which only the former has been approved for clinical use in Canada.